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Abstract 
Background: Recombinant human granulocyte‑macrophage colony‑stimulating factor (rhGM‑CSF) is a glycoprotein 
that has been approved by the FDA for the treatment of neutropenia and leukemia in combination with chemothera‑
pies. Recombinant hGM‑CSF is produced industrially using the baker’s yeast, Saccharomyces cerevisiae, by large‑scale 
fermentation. The methylotrophic yeast, Pichia pastoris, has emerged as an alternative host cell system due to its 
shorter and less immunogenic glycosylation pattern together with higher cell density growth and higher secreted 
protein yield than S. cerevisiae. In this study, we compared the pipeline from gene to recombinant protein in these 
two yeasts.
Results: Codon optimization in silico for both yeast species showed no difference in frequent codon usage. However, 
rhGM‑CSF expressed from S. cerevisiae BY4742 showed a significant discrepancy in molecular weight from those of 
P. pastoris X33. Analysis showed purified rhGM‑CSF species with molecular weights ranging from 30 to more than 
60 kDa. Fed‑batch fermentation over 72 h showed that rhGM‑CSF was more highly secreted from P. pastoris than S. 
cerevisiae (285 and 64 mg total secreted protein/L, respectively). Ion exchange chromatography gave higher purity 
and recovery than hydrophobic interaction chromatography. Purified rhGM‑CSF from P. pastoris was 327 times more 
potent than rhGM‑CSF from S. cerevisiae in terms of proliferative stimulating capacity on the hGM‑CSF‑dependent cell 
line, TF‑1.
Conclusion: Our data support a view that the methylotrophic yeast P. pastoris is an effective recombinant host for 
heterologous rhGM‑CSF production.
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Background
Human granulocyte-macrophage colony-stimulating 
factor (hGM-CSF), a glycosylated cytokine, plays a vital 
role in proliferation and differentiation of granulocytes 
and macrophages from bone marrow progenitor cells [1]. 
hGM-CSF also enhances cytotoxicity of macrophages 
and monocytes towards tumor cells [2], as well as tumor 
presentation of dendritic cells [1, 3]. Due to its stimula-
tory capacity on hematopoietic stem cells, recombinant 
hGM-CSF (rhGM-CSF) is recommended for therapeu-
tic use in combination with chemo- or radio-therapy for 
cancer or transplantation patients [4].
hGM-CSF comprises 127 amino acids. The pres-
ence of 2  N- and 4 O-glycosylation sites leads to differ-
ent glycoforms with molecular weights ranging from 14 
to 60 kDa [3]. The glycosylation of the protein affects its 
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pharmacokinetics, in  vivo half-life, immunogenicity and 
cytotoxicity [3].
rhGM-CSF is produced from bacteria, baker yeast or 
mammalian hosts [5]. rhGM-CSF produced in Escheri-
chia coli is biologically active but unstable in human 
plasma. It induces an immune reaction because N-formyl 
methionine (fMet) is its first amino acid. rhGM-CSF pro-
duced in mammalian hosts has a similar glycosylation 
pattern to the native human protein, but production rates 
are slow [6, 7]. The product from baker’s yeast, Saccha-
romyces cerevisiae, is glycosylated and approved by the 
FDA for the treatment of neutropenia and leukemia in 
combination with chemo- or radio-therapy for cancer or 
transplantation patients. The drawbacks of using S. cer-
evisiae are hyper-glycosylated products and low cell den-
sity growth.
The methylotrophic yeast Pichia pastoris has emerged 
as an alternative host due to its shorter and less immu-
nogenic glycans, higher density cell growth and higher 
secreted protein yields than S. cerevisiae. In this study, 
we show that P. pastoris secretes a higher yield of more 
active recombinant rhGM-CSF than S. cerevisiae.
Methods
In silico codon optimization
hGM-CSF coding sequences were from Gene Bank 
(Accession M11220). In silico codon optimization was 
done using DNA 2.0 software with P. pastoris and S. cer-
evisiae codon tables and optimized parameters [8]. The 
optimization evaluation was done via http://www.gcua.
schoedl.de with low (<20%) frequency codon usage dis-
played as hatched bars and very low (<10%) frequency 
codon usage as white bars.
Expression of rhGM‑CSF in P. pastoris and S. cerevisiae
Recombinant P. pastoris and S. cerevisiae rhGM-CSF 
clones were expressed as described previously [9, 10]. 
The expression of the rhGM-CSF was analyzed by SDS-
PAGE and immuno blot probed with an antibody against 
hGM-CSF (LifeSpan BioScience). Briefly, recombinant S. 
cerevisiae strain BY4742/hgm-csf was cultured in selec-
tive CSM-ura medium (6.7 g/L yeast nitrogen base with 
ammonium sulphate, 0.1  M sodium phosphate, sup-
plemented with amino acids lacking uracil [11]) supple-
mented with 2% glucose until the  OD600 of the culture 
was 0.5–1. The cells were then harvested and transferred 
into CSMG-ura medium (CSM supplemented with 
20 g/L galactose) with shaking at 230 rpm at 30 °C. The 
pH 6.0 of each medium was stabilized by 0.1 M sodium 
phosphate buffer. The sample supernatants were col-
lected after 72  h of induction and stored for further 
analysis.
Recombinant P. pastoris X33::hgm-csf was grown in 
10  mL BMGY medium (2% peptone, 1% yeast extract, 
0.34% yeast nitrogen base, 1% ammonium sulfate, 1% 
glycerol, and 0.4  mg/L biotin, buffered with 1/10 vol-
ume of pH 6.0 potassium phosphate buffer) at 30°C with 
constant shaking at 250 rpm until the culture reached an 
 OD600 of 2–4. The cells were harvested and re-suspended 
in 10  mL BMMY (0.5% methanol is substituted for 1% 
glycerol in BMGY) with the same growth conditions. For 
induction, methanol was added every 24 h to a final con-
centration of 0.5%. After 72 h, culture supernatants were 
collected by centrifugation for further analysis.
Fermentation of recombinant P. pastoris and S. cerevisiae
Recombinant yeast S. cerevisiae strain BY4742/hgm-
csf was batch-cultured in selective CSM(-ura) medium, 
pH 5.0 supplemented with 2% glucose until the culture 
reached an  OD600 of 0.5 to 1, and then transferred into 
3.18 L YP medium to a final  OD600 of 0.5 in a 5 L LiFlus-
GX fermenting vessel system (Biotron). Others growth 
parameters were temperature at 30  °C, aeration rate 1.5 
vvm (through a filter), and agitation speed 720 rpm. Every 
24  h, 40  g/L galactose was added at a rate of 6.7  mL/h. 
Samples were harvested at every 4  h and analyzed. 
Growth of the yeast cultures was monitored by optical 
density measurements at 600  nm. Protein secretion in 
the fermented medium was analyzed by SDS-PAGE and 
the protein concentration was determined using Brad-
ford’s method [12]. The supernatant was stored at −20 °C 
for later purification.
For P. pastoris expression [13], a flask contain-
ing 150  mL BMGY containing 0.4  µg/mL biotin was 
inoculated from a frozen glycerol stock. The inoculum 
seed flask was grown at 30  °C, 250  rpm, and 24  h until 
 OD600  =  2–6. A sterilized fermenter containing 2.5  L 
Fermentation Basal Salts medium supplemented with 4% 
glycerol and 11  mL  PTM1 trace salts was prepared, the 
pH adjusted to 5.0 with ammonium hydroxide, the tem-
perature set to 30  °C, agitation at 750 rpm and aeration 
to 5.0 vvm air. The culture in the inoculum seed flask was 
completely transferred into the fermenter in which the 
batch culture was grown for 24 h, until the glycerol was 
completely consumed. Glycerol feeding was initiated for 
about 4 h at a feed rate to 18.15 mL/h 50% w/v glycerol 
containing 1.2% v/v  PTM1 trace salts. Methanol feeding 
was then initiated for 72 h at a feed rate of 100% meth-
anol containing 1.2% v/v  PTM1 trace salts as follows: 
9 mL/h for 3 h; 18 mL/h for 3 h and then 27 mL/h. The 
supernatant was analyzed by SDS-PAGE every 4  h and 
the protein concentration was determined using Brad-
ford’s method [12]. The supernatant was stored at −20 °C 
for later purification.
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Ion exchange chromatography and hydrophobic 
interaction chromatography purification of recombinant 
rhGM‑CSF
rhGM-CSF was purified using hydrophobic interaction 
chromatography. A HiPrep Phenyl Fast Flow column was 
equilibrated in buffer A [(NH4)2SO4 2  M,  CH3COONa 
20 mM, pH 5.0]. Approximately 20 mL of filtered super-
natant was loaded onto the column at 1 mL/min. The col-
umn was then washed with 10 column volumes of buffer 
B. The bound protein was subsequently eluted with 
buffer B  (Na2HPO4 10.14 mM;  KH2PO4 1.76 mM; NaCl 
136.89 mM; KCl 2.68 mM, pH 7.4) in a step-wise manner, 
ranging from 5, 10, 20, 40, 60 and 100% buffer B. The tar-
get fractions were identified by SDS-PAGE. The protein 
was eluted maximally at 10 to 20% buffer B.
rhGM-CSF was alternatively purified using anion 
exchange chromatography at pH 7.5. A HiTrap Q Sepha-
rose Fast Flow column was equilibrated in 50 mM Tris-
HCl. Approximately 20  mL of filtered and desalted 
supernatant was loaded onto the column at 1  mL/min. 
The column was then washed with 10 column volumes 
of 50 mM Tris-HCl. The bound protein was subsequently 
Fig. 1 Relative adaptiveness (frequency of codon usage) of the sequence encodinghGM‑CSF prior (left column) and post (right column) in silico opti‑
mization for expression in P. pastoris and S. cerevisiae. Low (<20%) frequency codon usage is shown in hatched bars while very low (<10%) frequency 
codon usage is shown in white bars
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eluted in a step-wise manner with the NaCl concentra-
tion optimized over a range of 0–1  M NaCl in 50  mM 
Tris-HCl. The target fractions were identified by SDS-
PAGE. The protein was eluted maximally at 0.1–0.2  M 
NaCl.
Bioactivity of purified rhGM‑CSF
Purified rhGM-CSF from each yeast species was added 
to 1 ×  105 cells/mL of TF-1 (a GM-CSF dependent cell 
line) in RPMI plus 10% FBS to obtain a final rhGM-CSF 
concentration ranging from 2 × 104 to 2 × 10−1 pg/mL. 
100 µL of each combination was aliquoted into a 96-well 
plate and cultured for 72  h in a 5%  CO2 incubator. The 
proliferation of TF-1 cells was measured by using a 
CCK-8 kit at OD 450 nm according to the manufacturer’s 
instructions. Crude supernatants from P. pastoris and S. 
cerevisiae served as controls. LU (Laboratory unit) was 
calculated as follows:
Results
In silico optimization removes low frequency codon usage 
in both yeasts
In contrast to the native human sequence, both in silico-
optimized sequences show a high relative adaptiveness 
(Fig. 1, right column). These low (<20%, hatched bars) or 
very low (<10%, white bars) frequency codons were sub-
stituted for higher frequency codons. The optimization 
step did not introduce restriction enzyme(s) to the opti-
mized sequences (data not show) which facilitated the 
subsequent cloning steps.
Differences in the expression profile of rhGM‑CSF in the 
two yeast species
The expression profile of rhGM-CSF was analyzed using 
SDS-PAGE and probed with a specific antibody against 
hGM-CSF. The induction of P. pastoris with methanol led 
to the expression of several proteins (Fig. 2). Probing with 
a specific antibody showed the majority of the expressed 
rhGM-CSF ranged in size from 28–43  kDa with two 
minor bands at 17.8 and 24  kDa. In contrast, following 
induction of recombinant S. cerevisiae cells with galac-
tose, there was no difference compared to control cells 
(Fig.  3). Probing with a specific antibody showed the 
majority of expressed rhGM-CSF ranged in size from 30 
to 67 kDa.
Recombinant hGM‑CSF is highly secreted from P. pastoris
Time-course expression showed an accumulation of 
rhGM-CSF (Fig. 4). In the last 72 h, the secreted protein/
OD600 ratio was dramatically increased in P. pastoris. The 




the time course compared to 32 OD units for S. cerevisiae 
(Fig. 5). Consequently, this led to a higher total secreted 
protein yield per mL culture medium at 72 h post-induc-
tion (285 mg for P. pastoris vs 64 mg for S. cerevisiae).
Ion exchange chromatography is more efficient 
in recovery of rhGM‑CSF than hydrophobic interaction 
chromatography
Recombinant hGM-CSF produced in P. pastoris was 
eluted maximally at 10–20% buffer phosphate. The 
purity was 85.2% and the recovery yield was 53.8% (Fig. 6 
Fig. 2 The expression of rhGM‑CSF in P. pastoris analyzed by SDS‑
PAGE (a) and immunoblot probed with an anti‑hGM‑CSF antibody 
(b). M, molecular mass markers; 1, P. pastoris X33 culture supernatant 
72 h post‑induction with methanol; 2, P. pastoris X33::hgm‑csfculture 
supernatant 72 h post‑induction; 50 µL crude supernatant was pre‑
cipitated and loaded per lane
Fig. 3 The expression of rhGM‑CSF in S. cerevisiae analyzed by SDS‑
PAGE (a) and immunoblot probed with an anti‑hGM‑CSF antibody 
(b). M molecular markers; 1 supernatant from S. cerevisiae BY4742 
72 h post‑induction with galactose; 2, 3 and 4, supernatant from S. 
cerevisiae BY4742/pYES2‑hgm‑csf induced with galactose after 24, 48 
and 72 h, respectively 50 µL crude supernatant was precipitated and 
loaded per lane
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and  Table  1). In contrast, using ion exchange chroma-
tography, rhGM-CSF was eluted with 10 and 20% elu-
tion buffer; the purity ranged from 92 to 95%, and the 
recovery yield was 36–56% (Fig. 6 and Table 1). Collec-
tively, ion exchange chromatography was more efficient 
in recovery of rhGM-CSF than hydrophobic interaction 
chromatography. A similar result was also obtained for 
rhGM-CSF produced in S. cerevisiae (data not shown and 
Table 1).
Recombinant hGM‑CSF produced from P. pastoris shows 
high bioactivity on a GM‑CSF‑dependent cell line
The purity of a sample strongly affects its bioactivity. 
Thus to precisely evaluate bioactivity, rhGM-CSF pro-
duced from both yeasts was only tested with a purity 
above 80%. These samples were evaluated using a GM-
CSF-dependent cell line, namely TF-1. The response 
curves showed a typical sigmoidal cytokine response. 
To compare the responses, effective dose 50  (ED50) 
(pg/mL) and laboratory unit (LU) (units/mg) were cal-
culated from each curve as shown in Table 2. The  ED50 
of purified rhGM-CSF increased on going from protein 
Fig. 4 The secreted expression of rhGM‑CSF analyzed by SDS‑PAGE; hours post induction (h.p.i) are indicated for P. pastoris X33::hgm‑csf induced 
with methanol (a) or S. cerevisiae BY4742/pYES2‑hgm‑csf induced with galactose (b). M molecular mass markers; 50 µL crude supernatant was 
precipitated and loaded per lane
Fig. 5 OD and total secreted proteins in supernatants of P. pastoris 
X33::hgm‑csf induced with methanol or S. cerevisiae BY4742/pYES2‑
hgm‑csf induced with galactose was monitored over 72 h time course 
with 4 h intervals. Data are representative of three independent 
experiments
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produced using P. pastoris and IEC, P. pastoris and HIC, 
S. cerevisiae and IEC to S. cerevisiae and HIC. Nota-
bly, purified rhGM-CSF from P. pastoris using IEC had 
higher purity than protein from P. pastoris using HIC 
(Fig. 7).  
Discussion
Four publications describe rhGM-CSF expression in 
three different yeast systems, including the well-known 
yeasts S. cerevisiae, P. pastoris and Yarrowia lipolytica 
[14–17], but none conducts a head-to-head comparison. 
In the present study, we used an in silico-optimized syn-
thetic hGM-CSF gene in two yeast expression vectors. 
The expression patterns were similar to those previously 
published [14, 15, 17].
Using fed-batch fermentation, we obtained yields of 
rhGM-CSF of 9.5 and 180.3  mg/L from S. cerevisiae 
and P. pastoris respectively. The latter is higher than 
has been previously described [17], possibly because 
we used single-copy rather than high-copy integration. 
All published protocols on the purification of rhGM-
CSF combine two different purification steps to get 
above 95% purity [14–17]. In our study, we used a one-
step procedure to obtain greater than 95% purity.
The activity of purified rhGM-CSF from S. cerevisiae on 
TF-1 cells was 0.36 × 105 LU/mg, which is lower than that 
of the commercially available drug Leukine (rhGM-CSF). 
Table 1 Purification yield of rhGM-CSF from P. pastoris and S. cerevisiae using IEC with % elution buffer or HIC














Purity (%) 92.7 95.2 85.2 95.6 64.22 42.9
Purification yield (%) 56.9 35.9 53.8 21.0 30.8 0.5
Fig. 6 Purification of rhGM‑CSF from culture supernatants of P. pastoris X33::hgm‑csf induced with methanol analyzed by SDS‑PAGE. a Hydropho‑
bic interaction chromatography. M molecular mass markers, S supernatant after 72 h, F column flow‑through, E eluted fraction. b Ion exchange 
chromatography. M molecular mass markers, S supernatant after 72 h, F column flow‑through, E1–6 fractions eluted with NaCl (50, 100, 200, 400, 
600 and 1000 mM, respectively)
Table 2 Bioactivity of purified rhGM-CSF from P. pastoris and S. cerevisiae using IEC or HIC
ED50 (pg/mL) LU (units/mg) Response curve range 
(OD unit)
GM‑CSF from P. pastoris (IEC) 84.5 11.8 × 106 0.26
GM‑CSF from P. pastoris (HIC) 198.7 5.0 × 106 0.32
GM‑CSF from P. pastoris (crude) 1876 0.53 × 106 0.06
GM‑CSF from S. cerevisiae (IEC) 27,880 0.36 × 105 0.49
GM‑CSF from S. cerevisiae (crude) 37,238 0.27 × 105 0.05
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The discrepancy could be due to the glycosylation moiety 
added to rhGM-CSF [3] which in turn could have an effect 
on its bioactivity. The drug Leukine contains a non-glyco-
sylated rhGM-CSF in contrast to our purified, glycosylated 
rhGM-CSF. Purified rhGM-CSF from P. pastoris had an 
activity of 1.2x107 LU/mg. This activity is almost equal to 
the standard sample announced by WHO [18] and is two 
times higher than that of Leukine. Compared to previous 
data [17], our purified rhGM-CSF is 15 times less active. 
When compared with our E. coli-derived rhGM-CSF 
(non-glycosylated), our data show that rhGM-CSF is 1.5 
times lower than that of E. coli origin (unpublished data). 
With the same purity, rhGM–CSF from S. cerevisiae was 
327 times less active than that from P. pastoris.
Conclusion
In this study, we have been able to compare the pipeline 
from gene to recombinant protein between S. cerevi-
siae and P. pastoris. Our results suggest that rhGM-CSF 
expressed in P. pastoris is more active than the same pro-
tein from S. cerevisiae. To our knowledge, the data pre-
sented here are the first head-to-head comparison of S. 
cerevisiae and P. pastoris as host cells for rhGM–CSF 
production.
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